
Changyuan Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5109630/publications.pdf Version: 2024-02-01



CHANCYLLAN WANG

#	Article	IF	CITATIONS
1	Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway. Pharmacological Research, 2018, 130, 466-480.	3.1	146
2	Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2016, 59, 6580-6594.	2.9	84
3	A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailability. Journal of Colloid and Interface Science, 2017, 485, 91-98.	5.0	81
4	Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biology and Therapy, 2015, 16, 106-114.	1.5	76
5	Dioscin attenuates renal ischemia/reperfusion injury by inhibiting the TLR4/MyD88 signaling pathway via up-regulation of HSP70. Pharmacological Research, 2015, 100, 341-352.	3.1	72
6	Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway. International Immunopharmacology, 2016, 36, 132-141.	1.7	72
7	Dioscin alleviates lipopolysaccharide-induced inflammatory kidney injury via the microRNA let-7i/TLR4/MyD88 signaling pathway. Pharmacological Research, 2016, 111, 509-522.	3.1	71
8	Catalpol Inhibits Homocysteine-induced Oxidation and Inflammation via Inhibiting Nox4/NF-κB and GRP78/PERK Pathways in Human Aorta Endothelial Cells. Inflammation, 2019, 42, 64-80.	1.7	66
9	Potent anti-inflammatory effect of dioscin mediated by suppression ofÂTNF-α-induced VCAM-1, ICAM-1and EL expression via the NF-IºB pathway. Biochimie, 2015, 110, 62-72.	1.3	61
10	Pharmacokinetic Interaction between JBP485 and Cephalexin in Rats. Drug Metabolism and Disposition, 2010, 38, 930-938.	1.7	58
11	Dioscin Restores the Activity of the Anticancer Agent Adriamycin in Multidrug-Resistant Human Leukemia K562/Adriamycin Cells by Down-Regulating MDR1 via a Mechanism Involving NF-κB Signaling Inhibition. Journal of Natural Products, 2013, 76, 909-914.	1.5	58
12	Catalpol alleviates adriamycinâ€induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro. British Journal of Pharmacology, 2019, 176, 4558-4573.	2.7	58
13	Luteolin attenuates glucocorticoidâ€induced osteoporosis by regulatingÂERK/Lrpâ€5/GSKâ€3β signaling pathway in vivo and in vitro. Journal of Cellular Physiology, 2019, 234, 4472-4490.	2.0	57
14	Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. European Journal of Pharmacology, 2017, 806, 75-82.	1.7	56
15	Hepatoprotective effect of ginsenoside Rg1 from <i>Panax ginseng</i> on carbon tetrachlorideâ€induced acute liver injury by activating Nrf2 signaling pathway in mice. Environmental Toxicology, 2018, 33, 1050-1060.	2.1	56
16	Dioscin suppresses human laryngeal cancer cells growth via induction of cell-cycle arrest and MAPK-mediated mitochondrial-derived apoptosis and inhibition of tumor invasion. European Journal of Pharmacology, 2016, 774, 105-117.	1.7	55
17	Luteolin ameliorates LPS-induced acute liver injury by inhibiting TXNIP-NLRP3 inflammasome in mice. Phytomedicine, 2021, 87, 153586.	2.3	55
18	Total Flavonoids from Rosa laevigata Michx Fruit Ameliorates Hepatic Ischemia/Reperfusion Injury through Inhibition of Oxidative Stress and Inflammation in Rats. Nutrients, 2016, 8, 418.	1.7	51

#	Article	IF	CITATIONS
19	Hepatoprotective effect of rhein against methotrexate-induced liver toxicity. European Journal of Pharmacology, 2018, 834, 266-273.	1.7	50
20	Resveratrol Increases Antiâ€Proliferative Activity of Bestatin Through Downregulating Pâ€Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells. Journal of Cellular Biochemistry, 2016, 117, 1233-1239.	1.2	49
21	P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicology and Applied Pharmacology, 2016, 306, 27-35.	1.3	47
22	Targeting Pâ€glycoprotein and SORCIN: Dihydromyricetin strengthens antiâ€proliferative efficiency of adriamycin via MAPK/ERK and Ca ²⁺ â€mediated apoptosis pathways in MCFâ€7/ADR and K562/ADR. Journal of Cellular Physiology, 2018, 233, 3066-3079.	2.0	47
23	Rhizoma Dioscoreae Nipponicae polysaccharides protect HUVECs from H2O2-induced injury by regulating PPARγ factor and the NADPH oxidase/ROS–NF-κB signal pathway. Toxicology Letters, 2015, 232, 149-158.	0.4	46
24	Soluplus/TPGS mixed micelles for dioscin delivery in cancer therapy. Drug Development and Industrial Pharmacy, 2017, 43, 1197-1204.	0.9	46
25	Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor. Phytomedicine, 2017, 25, 83-92.	2.3	46
26	Disocin prevents postmenopausal atherosclerosis in ovariectomized LDLR-/- mice through a PGC-1α/ERα pathway leading to promotion of autophagy and inhibition of oxidative stress, inflammation and apoptosis. Pharmacological Research, 2019, 148, 104414.	3.1	46
27	Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis. Pharmacological Research, 2016, 108, 90-101.	3.1	45
28	Activating the PGC-1 <i>α</i> /TERT Pathway by Catalpol Ameliorates Atherosclerosis via Modulating ROS Production, DNA Damage, and Telomere Function: Implications on Mitochondria and Telomere Link. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	1.9	45
29	Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway. Free Radical Research, 2018, 52, 198-211.	1.5	44
30	Kaempferol-induced GPER upregulation attenuates atherosclerosis via the PI3K/AKT/Nrf2 pathway. Pharmaceutical Biology, 2021, 59, 1104-1114.	1.3	44
31	Dioscin alleviates dimethylnitrosamine-induced acute liver injury through regulating apoptosis, oxidative stress and inflammation. Environmental Toxicology and Pharmacology, 2016, 45, 193-201.	2.0	43
32	Development and evaluation of a novel drug delivery: Soluplus [®] /TPGS mixed micelles loaded with piperine <i>in vitro</i> and <i>in vivo</i> . Drug Development and Industrial Pharmacy, 2018, 44, 1409-1416.	0.9	42
33	OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. International Journal of Pharmaceutics, 2018, 537, 172-182.	2.6	41
34	CoenzymeQ10-Induced Activation of AMPK-YAP-OPA1 Pathway Alleviates Atherosclerosis by Improving Mitochondrial Function, Inhibiting Oxidative Stress and Promoting Energy Metabolism. Frontiers in Pharmacology, 2020, 11, 1034.	1.6	41
35	Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin. European Journal of Pharmaceutical Sciences, 2013, 50, 420-428.	1.9	40
36	Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). European Journal of Medicinal Chemistry, 2017, 133, 329-339.	2.6	40

#	Article	IF	CITATIONS
37	7-O-Geranylquercetin induces apoptosis in gastric cancer cells via ROS-MAPK mediated mitochondrial signaling pathway activation. Biomedicine and Pharmacotherapy, 2017, 87, 527-538.	2.5	38
38	JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats. Toxicology and Applied Pharmacology, 2013, 271, 285-295.	1.3	37
39	Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice. Pharmaceutical Research, 2015, 32, 3688-3698.	1.7	37
40	Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice. Food and Function, 2016, 7, 3716-3723.	2.1	37
41	Protective effects of ginsenoside Rg1 against lipopolysaccharide/ d -galactosamine-induced acute liver injury in mice through inhibiting toll-like receptor 4 signaling pathway. International Immunopharmacology, 2018, 61, 266-276.	1.7	36
42	Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Tumor Biology, 2016, 37, 8587-8597.	0.8	35
43	Naringin Inhibits TNF-α Induced Oxidative Stress and Inflammatory Response in HUVECs via Nox4/NF-κ B and PI3K/Akt Pathways. Current Pharmaceutical Biotechnology, 2014, 15, 1173-1182.	0.9	35
44	Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochemical Pharmacology, 2014, 92, 289-298.	2.0	34
45	Dioscin protects against ANIT–induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats. Toxicology and Applied Pharmacology, 2016, 305, 127-135.	1.3	34
46	Hepatoprotection of auraptene from peels of citrus fruits against thioacetamide-induced hepatic fibrosis in mice by activating farnesoid X receptor. Food and Function, 2018, 9, 2684-2694.	2.1	34
47	Involvement of Organic Anion-Transporting Polypeptides in the Hepatic Uptake of Dioscin in Rats and Humans. Drug Metabolism and Disposition, 2013, 41, 994-1003.	1.7	33
48	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. European Journal of Medicinal Chemistry, 2017, 135, 60-69.	2.6	33
49	Ginsenoside Rg1 protects against acetaminophen-induced liver injury via activating Nrf2 signaling pathway in vivo and in vitro. Regulatory Toxicology and Pharmacology, 2018, 98, 58-68.	1.3	33
50	Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Oncotarget, 2017, 8, 8622-8632.	0.8	33
51	Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. European Journal of Medicinal Chemistry, 2017, 142, 493-505.	2.6	30
52	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. Toxicology Letters, 2018, 295, 195-204.	0.4	30
53	Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity. Bioorganic and Medicinal Chemistry, 2017, 25, 3989-3996.	1.4	29
54	Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1. Scientific Reports, 2016, 6, 28403.	1.6	28

#	Article	IF	CITATIONS
55	Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/- mice via p66shc/cytochrome C cascade. Aging, 2020, 12, 2049-2069.	1.4	28
56	MDR1 and OAT1/OAT3 Mediate the Drug-Drug Interaction between Puerarin and Methotrexate. Pharmaceutical Research, 2014, 31, 1120-1132.	1.7	27
57	Alpha-lipoic acid defends homocysteine-induced endoplasmic reticulum and oxidative stress in HAECs. Biomedicine and Pharmacotherapy, 2016, 80, 63-72.	2.5	27
58	Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. Phytomedicine, 2019, 53, 134-142.	2.3	27
59	Adenine: an important drug scaffold for the design of antiviral agents. Acta Pharmaceutica Sinica B, 2015, 5, 431-441.	5.7	26
60	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. European Journal of Medicinal Chemistry, 2017, 126, 444-455.	2.6	26
61	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. European Journal of Medicinal Chemistry, 2018, 143, 1847-1857.	2.6	26
62	Effects of calycosin against highâ€fat dietâ€induced nonalcoholic fatty liver disease in mice. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 533-542.	1.4	25
63	Organic anion transporters and PI3K–AKT–mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein. Journal of Cellular Physiology, 2020, 235, 3309-3319.	2.0	25
64	Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 5505-5512.	1.4	24
65	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a <i>N</i> ,9-Diphenyl-9 <i>H</i> -purin-2-amine Scaffold. ACS Medicinal Chemistry Letters, 2016, 7, 1050-1055.	1.3	24
66	Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. European Journal of Medicinal Chemistry, 2016, 110, 195-203.	2.6	24
67	Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro. Toxicology and Applied Pharmacology, 2018, 348, 105-116.	1.3	24
68	Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines. Bioorganic Chemistry, 2020, 94, 103408.	2.0	23
69	Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury. Biochemical Pharmacology, 2017, 146, 127-138.	2.0	22
70	Hepatoprotection of auraptene from the peels of citrus fruits against 17α-ethinylestradiol-induced cholestasis in mice by activating farnesoid X receptor. Food and Function, 2019, 10, 3839-3850.	2.1	22
71	Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells. European Journal of Medicinal Chemistry, 2019, 172, 154-162.	2.6	22
72	Isoliquiritigenin alleviates LPS/ D-GalN-induced acute liver failure by activating the PGC-1α/ Nrf2 pathway to reduce oxidative stress and inflammatory response. International Immunopharmacology, 2021, 100, 108159.	1.7	22

#	Article	IF	CITATIONS
73	PEPT1- and OAT1/3-mediated drug–drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human. European Journal of Pharmaceutical Sciences, 2014, 63, 77-86.	1.9	21
74	Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro. International Journal of Pharmaceutics, 2015, 495, 588-598.	2.6	21
75	Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity. European Journal of Pharmacology, 2018, 824, 64-71.	1.7	21
76	Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Cellular Physiology and Biochemistry, 2018, 51, 1616-1631.	1.1	21
77	Protective effect of cilastatin against diclofenacâ€induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters. British Journal of Pharmacology, 2020, 177, 1933-1948.	2.7	21
78	PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. European Journal of Pharmacology, 2009, 612, 9-14.	1.7	20
79	OATP and MRP2-mediated hepatic uptake and biliary excretion of eprosartan in rat and human. Pharmacological Reports, 2014, 66, 311-319.	1.5	20
80	Dioscin attenuates gastric ischemia/reperfusion injury through the down-regulation of PKC/ERK1/2 signaling via PKCα and PKCβ2 inhibition. Chemico-Biological Interactions, 2016, 258, 234-244.	1.7	20
81	Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs). Acta Pharmaceutica Sinica B, 2019, 9, 986-996.	5.7	20
82	Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting Pâ€glycoprotein. Journal of Cellular Physiology, 2019, 234, 3685-3696.	2.0	19
83	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. Bioorganic and Medicinal Chemistry, 2017, 25, 765-772.	1.4	18
84	Inhibitory Effect of Valsartan on the Intestinal Absorption and Renal Excretion of Bestatin in Rats. Journal of Pharmaceutical Sciences, 2014, 103, 719-729.	1.6	17
85	P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. Pharmacological Reports, 2018, 70, 243-250.	1.5	17
86	Soluplus [®] /TPGS mixed micelles for co-delivery of docetaxel and piperine for combination cancer therapy. Pharmaceutical Development and Technology, 2020, 25, 107-115.	1.1	17
87	Mixed micelles of TPGS and Soluplus [®] for co-delivery of paclitaxel and fenretinide: <i>inÂvitro</i> and <i>inÂvivo</i> anticancer study. Pharmaceutical Development and Technology, 2020, 25, 865-873.	1.1	17
88	Oleanolic acid-loaded PLGA-TPGS nanoparticles combined with heparin sodium-loaded PLGA-TPGS nanoparticles for enhancing chemotherapy to liver cancer. Life Sciences, 2016, 165, 63-74.	2.0	16
89	Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. Bioorganic and Medicinal Chemistry, 2017, 25, 6313-6321.	1.4	16
90	Promising galactose-decorated biodegradable poloxamer 188-PLGA diblock copolymer nanoparticles of resibufogenin for enhancing liver cancer therapy. Drug Delivery, 2017, 24, 1302-1316.	2.5	15

#	Article	IF	CITATIONS
91	Preparation of a thiols βâ€cyclodextrin/gold nanoparticlesâ€coated open tubular column for capillary electrochromatography enantioseparations. Journal of Separation Science, 2020, 43, 2209-2216.	1.3	15
92	Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR. Phytomedicine, 2021, 90, 153629.	2.3	15
93	Dioscin enhances methotrexate absorption by down-regulating MDR1 in vitro and in vivo. Toxicology and Applied Pharmacology, 2014, 277, 146-154.	1.3	14
94	Methotrexate-bestatin interaction: Involvement of P-glycoprotein and organic anion transporters in rats. International Journal of Pharmaceutics, 2014, 465, 368-377.	2.6	14
95	Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer. Pharmaceutical Research, 2016, 33, 2828-2843.	1.7	14
96	Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro. Biomedicine and Pharmacotherapy, 2018, 103, 915-922.	2.5	14
97	Dihydroartemisinin and doxorubicin co-loaded Soluplus [®] -TPGS mixed micelles: formulation characterization, cellular uptake, and pharmacodynamic studies. Pharmaceutical Development and Technology, 2019, 24, 1125-1132.	1.1	14
98	Regio- and stereo-selective oxidation of \hat{I}^2 -boswellic acids transformed by filamentous fungi. RSC Advances, 2015, 5, 12717-12725.	1.7	13
99	Bezafibrate–mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats. European Journal of Pharmaceutical Sciences, 2016, 81, 119-128.	1.9	13
100	Yangonin protects against estrogen–induced cholestasis in a farnesoid X receptor-dependent manner. European Journal of Pharmacology, 2019, 857, 172461.	1.7	13
101	Resveratrol enhances the protective effects of JBP485 against indomethacin-induced rat intestinal damage in vivo and vitro through up-regulating oligopeptide transporter 1 (Pept1). Biomedicine and Pharmacotherapy, 2019, 111, 251-261.	2.5	13
102	Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin. Asian Journal of Pharmaceutical Sciences, 2020, 15, 252-263.	4.3	13
103	Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorganic and Medicinal Chemistry, 2020, 28, 115254.	1.4	13
104	Targeting renal <scp>OATs</scp> to develop renal protective agent from traditional Chinese medicines: Protective effect of Apigenin against Imipenemâ€induced nephrotoxicity. Phytotherapy Research, 2020, 34, 2998-3010.	2.8	13
105	Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. Biomedicine and Pharmacotherapy, 2020, 125, 110032.	2.5	13
106	Yangonin inhibits ethanol-induced hepatocyte senescence via miR-194/FXR axis. European Journal of Pharmacology, 2021, 890, 173653.	1.7	13
107	Molecular Mechanisms of Biliary Excretion of Cefditoren and the Effects of Cefditoren on the Expression Levels of Hepatic Transporters. Drug Metabolism and Pharmacokinetics, 2010, 25, 320-327.	1.1	12
108	Inhibitory Effect of Zinc on the Absorption of JBP485 via the Gastrointestinal Oligopeptide Transporter (PEPT1) in Rats. Drug Metabolism and Pharmacokinetics, 2011, 26, 494-502.	1.1	12

#	Article	IF	CITATIONS
109	C -2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR T790M mutant. Bioorganic and Medicinal Chemistry, 2017, 25, 2724-2729.	1.4	12
110	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines. Bioorganic and Medicinal Chemistry, 2018, 26, 4179-4186.	1.4	12
111	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. Bioorganic Chemistry, 2021, 106, 104385.	2.0	12
112	Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant. Cardiovascular Drugs and Therapy, 2022, 36, 121-129.	1.3	12
113	The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. European Journal of Pharmaceutical Sciences, 2014, 52, 41-47.	1.9	11
114	Puerarin sensitized <scp>K562</scp> / <scp>ADR</scp> cells by inhibiting <scp>NFâ€₽B</scp> pathway and inducing autophagy. Phytotherapy Research, 2021, 35, 1658-1668.	2.8	11
115	Decreased liver distribution of entecavir is related to down-regulation of Oat2/Oct1 and up-regulation of Mrp1/2/3/5 in rat liver fibrosis. European Journal of Pharmaceutical Sciences, 2015, 71, 73-79.	1.9	10
116	Organic anion transporters 1 (OAT1) and OAT3 meditated the protective effect of rhein on methotrexate-induced nephrotoxicity. RSC Advances, 2017, 7, 25461-25468.	1.7	10
117	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma. Bioorganic Chemistry, 2020, 95, 103542.	2.0	10
118	Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). ChemMedChem, 2020, 15, 182-187.	1.6	10
119	Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation. International Immunopharmacology, 2019, 75, 105833.	1.7	9
120	Phosphocreatine Promotes Osteoblastic Activities in H2O2-Induced MC3T3-E1 Cells by Regulating SIRT1/FOXO1/PGC-11± Signaling Pathway. Current Pharmaceutical Biotechnology, 2021, 22, 609-621.	0.9	9
121	Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC. European Journal of Medicinal Chemistry, 2021, 223, 113626.	2.6	8
122	Isoliquiritigenin-mediated miR-23a-3p inhibition activates PGC-1α to alleviate alcoholic liver injury. Phytomedicine, 2022, 96, 153845.	2.3	8
123	Simultaneous Determination of Resibufogenin and Its Major Metabolite 3-epi-Resibufogenin in Rat Plasma by HPLC Coupled with Tandem Mass Spectrometry. Chromatographia, 2012, 75, 103-109.	0.7	7
124	Protective effects of formononetin against rhabdomyolysis-induced acute kidney injury by upregulating Nrf2 in vivo and in vitro. RSC Advances, 2016, 6, 110874-110883.	1.7	7
125	Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer. Bioorganic Chemistry, 2019, 89, 102994.	2.0	7
126	Catalpol-Induced AMPK Activation Alleviates Cisplatin-Induced Nephrotoxicity through the Mitochondrial-Dependent Pathway without Compromising Its Anticancer Properties. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	7

#	Article	IF	CITATIONS
127	Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma. Bioorganic Chemistry, 2021, 116, 105330.	2.0	7
128	Involvement of organic cation transporter 2 in the metformin-associated increased lactate levels caused by contrast-induced nephropathy. Biomedicine and Pharmacotherapy, 2018, 106, 1760-1766.	2.5	6
129	Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC. Bioorganic Chemistry, 2021, 114, 105045.	2.0	6
130	Activation of <scp>PGC</scp> â€lα via isoliquiritigeninâ€induced downregulation of <scp>miR</scp> â€l38â€5p alleviates nonalcoholic fatty liver disease. Phytotherapy Research, 2022, 36, 899-913.	2.8	6
131	RAPID SEPARATION OF FLAVONOIDS FROM HYDROLYSIS PRODUCTS OFEpimedium koreanum. Journal of Liquid Chromatography and Related Technologies, 2013, 36, 1163-1176.	0.5	5
132	Catalpol attenuates oxidative stress and promotes autophagy in TNF-α-exposed HAECs by up-regulating AMPK. RSC Advances, 2017, 7, 52561-52572.	1.7	5
133	Liver uptake of cefditoren is mediated by OATP1B1 and OATP2B1 in humans and Oatp1a1, Oatp1a4, and Oatp1b2 in rats. RSC Advances, 2017, 7, 30038-30048.	1.7	5
134	Pharmacokinetic changes of cefdinir and cefditoren and its molecular mechanisms in acute kidney injury in rats. Journal of Pharmacy and Pharmacology, 2018, 70, 1503-1512.	1.2	5
135	Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485). Journal of Medicinal Chemistry, 2019, 62, 7708-7721.	2.9	5
136	Fenretinide-polyethylene glycol (PEG) conjugate with improved solubility enhanced cytotoxicity to cancer cell and potent <i>inÂvivo</i> efficacy. Pharmaceutical Development and Technology, 2020, 25, 962-970.	1.1	5
137	Honokiol Prodrug Nanoparticles Based on In Situ Albumin Binding for Long Circulation and High Tumor Uptake. ACS Medicinal Chemistry Letters, 2021, 12, 1589-1595.	1.3	5
138	Catalpol prevents alteration of cholesterol homeostasis in non-alcoholic fatty liver disease viaÂattenuating endoplasmic reticulum stress and NOX4 over-expression. RSC Advances, 2017, 7, 1161-1176.	1.7	4
139	Organic Anion–Transporting Polypeptide and Efflux Transporter–Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. Journal of Pharmaceutical Sciences, 2017, 106, 2515-2523.	1.6	4
140	Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer. Chemical Biology and Drug Design, 2018, 92, 1988-1997.	1.5	3
141	RAPID AND SENSITIVE DETERMINATION OF JBP485 BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND ITS APPLICATION IN PHARMACOKINETICS IN RAT. Journal of Liquid Chromatography and Related Technologies, 2011, 34, 350-359.	0.5	2
142	Rapid and Selective LC–MS–MS Method for the Determination of cyclo-trans-4-l-Hydroxyprolyl-l-serine (JBP485) in Rat Plasma. Chromatographia, 2011, 73, 481-486.	0.7	2
143	A stronger reversal effect of the combination of dasatinib and menadione on P-gp-mediated multidrug resistance in human leukemia K562/Adr cell line. RSC Advances, 2017, 7, 17227-17235.	1.7	2
144	Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128238.	1.0	2

#	Article	IF	CITATIONS
145	Substrate-dependent Inhibition of Hypericin on Human Carboxylesterase 2: Implications for Herb-drug Combination. Current Drug Metabolism, 2022, 23, 38-44.	0.7	2
146	Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 440-449.	0.9	2
147	Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through inhibition of organic anion transporter 1/3 in rats. Asian Journal of Pharmaceutical Sciences, 2019, 14, 677-686.	4.3	1
148	Comparison of the Inhibitory Effects of Clotrimazole and Ketoconazole against Human Carboxylesterase 2. Current Drug Metabolism, 2021, 22, 391-398.	0.7	1
149	α-Lipoic acid protects HAECs from high glucose-induced apoptosis via decreased oxidative stress, ER stress and mitochondrial injury. RSC Advances, 2015, 5, 70726-70736.	1.7	Ο
150	In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity. Current Drug Metabolism, 2021, 22, .	0.7	0
151	Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128464.	1.0	0
152	Unraveling the Structure-Dependent Inhibitory Effects of Ginsenoside Series Compounds on Human Cytochrome P450 1B1. Current Drug Metabolism, 2022, 23, 553-561.	0.7	0